MPLNET.com » Test Menu » ABL Kinase Gene Mutation Analysis; Gleevec® Resistance Client Login | Email | Phone: 1.800.932.2943

ABL Kinase Gene Mutation Analysis; Gleevec® Resistance

Test Code

M ABL G*

Test Synonyms

ABL kinase domain gene sequencing

Associations

chronic myelogenous leukemia (CML), acute lymphoblastic leukemia (ALL), allogeneic bone marrow transplantation, minimal residual disease (MRD), molecular remission, Gleevec® resistance

Methodology

Quantitative reverse transcriptase PCR (RT-PCR), Semi-nested PCR, Bi-directional DNA sequencing
Testing is performed at MolecularMD of Portland, Oregon pursuant to patents.

Turnaround Time

10-14 days

Specimen Requirements

10.0 mL (min. 9.0 mL) peripheral blood in EDTA
2.0 mL (min. 1.0 mL) bone marrow in EDTA

Specimen Stability
Specimen must be received by MPLN within 36 hours of collection
Stable at 2-8°C
Storage & Handling

Ship peripheral blood and bone marrow at refrigerated temperature.
Please notify us if specimen is to arrive after 1 p.m. on Friday or Saturday.

Causes for Rejection

Specimen > 48 hours old;
Specimen clotted;
Stored or shipped at incorrect temperature;
Incorrect anticoagulant;
Insufficient specimen volume

Reference Range

ABL Kinase domain mutation(s) detected and characterized / not detected

Description

MolecularMD has designed and validated bi-directional Sanger sequencing assays to identify mutations in the p210 and p190 transcripts of the BCR-ABL1 fusion gene. Our assay spans an extended region including the kinase and SH2-SH3 regulatory domains and is able to detect over 40 amino acid substitutions including the T315I mutation.

References
  1. Cell Cycle 2011; 10:250-260 2. Blood 2011; 116:3278-3285
Trademarks

Gleevec® is a registered trademark of the Novartis Pharmaceuticals Corporation.

Keywords
cml abl gleevec chronic myelogenous leukemia acute lymphoblastic leukemia abl kinase domain gene sequencing